comunicati
- The study1, a randomised controlled trial undertaken in Denmark, investigated the long-term effects of nasal high flow therapy for COPD patients already being treated with long-term oxygen therapy.
The trial showed statistically significant results, with the primary outcome being a significant reduction in patients’ exacerbation rate, or worsening of their condition (from 4.95 to 3.12 per patient per year, p
© RIPRODUZIONE RISERVATA
